Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (187)	8/2/2007 8:02:15 PM
From: dr.praveen	Read Replies (1) of 285

I thought the efficacy data was quite good on TD and it is a needle free patch. So the uptake should be good and a potential mkt of 400M?. The 2 things I want to look for are any side effects coz of the immunogenicity(on frequent and prolonged use). Any further antigen antibody reactions? Duration of the efficacy? But the efficacy shown is pretty good and we can see their full data set to be released soon. Iomai announced a couple of months ago that the interim Phase 1 clinical results of its patch vaccine for seasonal influenza didn't even have equal immune response as that of the needle vaccinations. So mostly they need to change the antigen and add an year more time for devp and a new partner. It works but the problem is to find the right antigen. Glad it was not the same case in TD. I agree it is cheap based on today's data and the bad mkt conditions. Praveen (I own some) Thanks for the wishes!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next